Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
DNA methylation of PSAT1 determines response to tamoxifen treatment
July 14th, 2005
DNA methylation of PSAT1 plays a key role in determining the response to endocrine therapy in women with recurrent "To understand the biological basis of resistance to endocrine therapy is of utmost importance in patients with steroid hormone receptor-positive breast cancer," oncologists in Germany argued. "Not only will this allow us prediction of therapy success, it may also lead to novel therapies for patients resistant to current endocrine therapy." "DNA methylation in the promoter regions of genes is a prominent epigenetic gene silencing mechanism that contributes to breast cancer biology," noted J.W.M. Martens and colleagues working at...
Source: Women's Health Weekly (2005-07-14)
|
